TEL AVIV: About 48 hours into his new job as CEO of Teva Pharmaceutical Industries Ltd, Kare Schultz is already US$2.8bil in the hole.
Shareholders shaved that much off the company’s market value after the world’s largest maker of copycat drugs failed to dispel worries that the worst may not be over. Schultz, 56, tried.
